The present findings demonstrated that EFM improved, diarrhea and gastrointestinal symptoms, and life quality in HER-2 positive breast cancer patients receiving the combination therapy of lapatinib and capecitabine (Figure 3). The gene discussed is ERBB2; the disease is breast carcinoma.